| Literature DB >> 32411334 |
Ana Paula C R Ferraz1, Alessandra Sussulini2, Jéssica L Garcia1, Mariane R Costa1, Fabiane V Francisqueti-Ferron1, Artur J T Ferron1, Carol Cristina V de A Silva1, José Eduardo Corrente1, Vanessa M Manfio1, Vickeline Namba1, Giuseppina P P Lima3, Bismarque S Pereira1, Denise Fecchio1, Igor O Minatel3, Klinsmann C Dos Santos1, Camila R Corrêa1.
Abstract
Solanum paniculatum L. or popularly known as "jurubeba" is an herbal medicinal plant. A few studies have investigated its biological effects; however, research aimed at elucidating the redox balance effects from its fruits has not been reported so far. ROS interplays in various fields of medicine such as chemotherapy. Here, we evaluated antioxidant and inflammatory activities of the hydroethanolic extract of Solanum Paniculatum L. (HESPL) fruits in breast cancer cells, as well as its phytochemical profile. The antioxidant profile (carotenoids and phenolic compounds) was obtained by HPLC-DAD-UV and HPLC-APCI-MS. Cancer cell lines and human vein endothelial cells (HUVECs) were cultivated and treated with 1.87-30 μg/mL of HESPL for 24 hrs. Cytotoxicity, oxidative, and inflammation biomarkers were evaluated. The dose of 30 μg/mL of the HESPL extract presented cytotoxicity in the MCF-7 cell line. However, for MDA-MB-231, the cytotoxicity was observed in the dose of 1.87 g/mL. The 1.87 μg/mL and 3.75 μg/mL doses decreased the concentration of IL-6 in MCF-7 cells. In the MDA-MB-231 cells, the HESPL did not decrease the IL-6 concentration; however, in the doses of 15 and 30 μg/mL, an increase in this parameter was observed. The HESPL increased IL-1β concentration in HUVECs. The ROS level in MCF-7 was elevated only at the 30 μg/ml dose. Regarding MDA-MB-231, HESPL promoted increased ROS levels at all doses tested. HUVEC showed no increase in ROS under any dose. HESPL treatment may modulate cytotoxicity, ROS, and cytokine levels due to its phytochemical profile, and it has shown an antioxidant or anti-inflammatory effect.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32411334 PMCID: PMC7204104 DOI: 10.1155/2020/7240216
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
SRM transitions for total carotenoids.
| Compound name | [M+H]+ ( | Fragment ion | Declustering potential (V) |
|---|---|---|---|
| Lutein | 569.0 | 476.0 | 80 |
| 175.0 | |||
| 551.0 | |||
| 533.0 | |||
|
| |||
| Zeaxanthin | 569.0 | 551.1 | 50 |
| 533.1 | |||
| 395.0 | |||
| 93.0 | |||
| 135.1 | |||
|
| |||
|
| 553.5 | 119.0 | 50 |
|
| |||
|
| 553.0 | 135.0 | 50 |
| 495.0 | |||
| 461.0 | |||
|
| |||
|
| 123.0 | ||
| 537.0 | 481.0 | 50 | |
| 444.1 | |||
| 177.2 | |||
| 445.4 | |||
|
| |||
|
| 537.0 | 413.3 | 50 |
| 269.2 | |||
Phytochemical profile of HESPL determined by HPLC-DAD-UV.
| Analyte | RT | Linearity range (ng/ | LOD/LOQ (ng/ |
|
| SD (%) | CV (%) |
|---|---|---|---|---|---|---|---|
| Carotenoids | |||||||
| Lutein | 3.449 | 5-100 | 1.45/5 | 0.9988 | 103.70 | 2.3049 | 2.222719 |
| Zeaxanthin | 4.133 | 2.28-36.5 | 0.80/2.28 | 0.9972 | 8.9 | 0.48608 | 5.461573 |
|
| 9.017 | 5.30-84.9 | 0.97/5.30 | 0.9963 | 8.8 | 0.5913 | 6.719318 |
|
| 15.666 | 15.6-250 | 0.89/15.6 | 0.9821 | 8.7 | 1.1533 | 0.131655 |
| Vitamin E | |||||||
|
| 5.333 | 0.075-2.42 | 1.09/0.075 | 0.9999 | 1.6 | 0.00206 | 0.12875 |
| Phenols | |||||||
| Chlorogenic acid | 3.517 | 10-500 | 1.40/10 | 0.9956 | 17.5 | 0.7415 | 4.237143 |
| Flavonoids | |||||||
| Caffeic acid | 6.617 | 10-500 | 1.30/10 | 0.9991 | 23.9 | 0.9641 | 4.033891 |
| Quercetin | 19.12 | 10-500 | 1.33/10 | 0.9999 | 2.9 | 0.1306 | 4.503448 |
Figure 1Carotenoid profile of Solanum paniculatum L. by HPLC-APCI-MS: (a) lutein compound in the sample; (b) lutein standard.
Figure 2% cell viability from MCF-7, MDA-MB-231, and HUVECs. ∗Versus control when p < 0.05. The viability was determined by the MTT assay. The dose of 30 μg/mL presented cytotoxicity.
Figure 3Different doses of HESPL effect in interleukin-6: (a) MCF-7 cells, (b) MDA-MB-231 cells, and (c) different doses of HESPL effect in IL-1β in the cell lines. ∗Versus control when p < 0.05. The dose of 3.75 μg/mL diminished significantly compared with other doses. On the other hand, the doses of 15 and 30 μg/mL were increased in MDA-MB-231, and for IL-1β, the dose 3.75 μg/mL was enhanced.
Figure 4ROS parameter from MCF-7, MDA-MB-231, and HUVECs. ∗Versus control when p < 0.05. The ROS was enhanced in all doses tested in invasive cells, and the dose 30 μg/mL was increased in MCF-7 cells.
Figure 5Cell flux analysis in MCF-7 cells: (a) 30 μg/mL treatment; (b) control.